SCHEMBL3073610

SCHEMBL3073610

Cc1ccn2ncc(C(=O)O)c2c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHB3 P54753 5/20 0.56
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
TGFBR1 P36897 2/20 0.41
CSNK2A1 P68400 1/20 0.41
KMO O15229 1/20 0.39
MGLL Q99685 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13139955 0.87 EPHB3 (0.56) EPHB3KDM4EALDH1A1GAAPKM
SCHEMBL21083418 0.85 EPHB3 (0.55) EPHB3LMNAHTTTGFBR1
SCHEMBL17320982 0.83 EPHB3 (0.56) EPHB3KDM4EALDH1A1LMNAHTT
SCHEMBL19657530 0.83 EPHB3 (0.63) EPHB3KDM4EALDH1A1GAALMNA
SCHEMBL13139964 0.81 EPHB3 (0.52) EPHB3KDM4EALDH1A1GAAPKM
SCHEMBL13139980 0.81 EPHB3 (0.62) EPHB3KDM4EALDH1A1GAALMNA
SCHEMBL28543731 0.81 EPHB3 (0.41) EPHB3KDM4EALDH1A1TGFBR1L3MBTL1
SCHEMBL29014099 0.81 NPC1 (0.49) EPHB3KDM4EALDH1A1GAATGFBR1
SCHEMBL3073456 0.80 ALDH1A1 (0.52) EPHB3KDM4EALDH1A1GAALMNA
SCHEMBL24369482 0.80 EPHB3 (0.59) EPHB3KDM4EALDH1A1HTTKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
EP-4573080-A1 INDANE AND COUMARAN DERIVATIVES AS FAST SKELETAL MUSCLE MYOSIN INHIBITORS Cytokinetics, Inc. (US) 2025-06-25 EP disclosed
WO-2025072330-A1 KIT INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-04-03 WO disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 US disclosed
CN-113164458-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-13 CN disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
US-11993601-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV 2024-05-28 US disclosed
WO-2024040190-A1 INDANE AND COUMARAN DERIVATIVES AS FAST SKELETAL MUSCLE MYOSIN INHIBITORS CYTOKINETICS, INCORPORATED (US) 2024-02-22 WO disclosed
WO-2018059314-A1 AZABICYCLE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2018-04-05 WO disclosed
US-9296746-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-03-29 US disclosed
EP-2927229-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-10-07 EP disclosed
US-20150266872-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-24 US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-09 US disclosed
EP-2176260-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-04-21 EP disclosed
WO-2009008748-A1 PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2009-01-15 WO disclosed
US-5200415-A Serotonin receptor antagonists; antiemetics, antianxietics ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1993-04-06 US disclosed
EP-0483836-A1 Pyrazolo [1,5-a] pyridine-3-carboxylic acid derivatives, their preparation process and their use ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1992-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH EPHB3 1882/4885KDM4E 3565/4885ALDH1A1 587/4885
US-20150266872-A1 HETEROCYCLIC COMPOUND HTT, BDNF, SNCA EPHB3 3604/4885KDM4E 1874/4885ALDH1A1 419/4885
US-20100226881-A1 PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY TP53, PNPO, DPYD EPHB3 2757/4885KDM4E 2333/4885ALDH1A1 588/4885
US-11993601-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP EPHB3 3144/4885KDM4E 2800/4885ALDH1A1 344/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP EPHB3 3144/4885KDM4E 2800/4885ALDH1A1 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.